Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05419011CT.gov Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lynch Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ad5 cea vaccine (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Aspirin | M.D. Anderson Cancer Center | P3 | BB |
| Naproxen | M.D. Anderson Cancer Center | P2 | B |
| Acetylsalicylic Acid Lysinate | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Fluorouracilum | National Cancer Institute (NCI) | P3 | B |
| Secretin | Johns Hopkins University | P3 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Atezolizumab | National Cancer Institute (NCI) | P3 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P3 | B |
+17 more in the Lynch Syndrome cohort
Other indications for ad5 cea vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P2 | CCC · 53 |
| Colorectal Carcinoma | — | P2 | CCC · 51 |
| Lung Cancer | — | P1/2 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ad5 cea vaccine in Lynch Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ad5-cea-vaccine-lynch-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →